547
Views
7
CrossRef citations to date
0
Altmetric
Laboratory Studies

Effect of rosiglitazone on cisplatin-induced nephrotoxicity

, , , , , , & show all
Pages 368-371 | Received 24 Sep 2009, Accepted 10 Dec 2009, Published online: 06 Apr 2010

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Gurkan Genc, Ali Okuyucu, Bilge Can Meydan, Oguzhan Yavuz, Ozlem Nisbet, Murat Hokelek, Abdulkerim Bedir & Ozan Ozkaya. (2014) Effect of free creatine therapy on cisplatin-induced renal damage. Renal Failure 36:7, pages 1108-1113.
Read now

Articles from other publishers (6)

Chun-yan Fang, Da-yong Lou, Li-qin Zhou, Jin-cheng Wang, Bo Yang, Qiao-jun He, Jia-jia Wang & Qin-jie Weng. (2021) Natural products: potential treatments for cisplatin-induced nephrotoxicity. Acta Pharmacologica Sinica 42:12, pages 1951-1969.
Crossref
Yimin Wang, Xiao Luo, Hao Pan, Wei Huang, Xueping Wang, Huali Wen, Kezhen Shen & Baiye Jin. (2015) Pharmacological inhibition of NADPH oxidase protects against cisplatin induced nephrotoxicity in mice by two step mechanism. Food and Chemical Toxicology 83, pages 251-260.
Crossref
Hao Pan, Kezhen Shen, Xueping Wang, Hongzhou Meng, Chaojun Wang & Baiye Jin. (2014) Protective Effect of Metalloporphyrins against Cisplatin-Induced Kidney Injury in Mice. PLoS ONE 9:1, pages e86057.
Crossref
Parveen Kumar, Krishna Shastrula Prashanth, Anil Bhanudas Gaikwad, Mohit Vij, Chandana C. Barua & Babul Bezbaruah. (2013) Disparity in actions of rosiglitazone against cisplatin-induced nephrotoxicity in female Sprague-Dawley rats. Environmental Toxicology and Pharmacology 36:3, pages 883-890.
Crossref
Mona F. Mahmoud & Shimaa M. El Shazly. (2013) Pioglitazone protects against cisplatin induced nephrotoxicity in rats and potentiates its anticancer activity against human renal adenocarcinoma cell lines. Food and Chemical Toxicology 51, pages 114-122.
Crossref
Jichun Yang, Yunfeng Zhou & Youfei Guan. (2012) PPARγ as a therapeutic target in diabetic nephropathy and other renal diseases. Current Opinion in Nephrology & Hypertension 21:1, pages 97-105.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.